ABCL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABCL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AbCellera Biologics has the Growth Rank of 5.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, AbCellera Biologics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Growth Rank distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Growth Rank falls into.
Thank you for viewing the detailed overview of AbCellera Biologics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Thermopylae Holdings Ltd. | 10 percent owner | 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
John S. Montalbano | director | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Michael R Hayden | director | C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Veronique Lecault | director, officer: Chief Operating Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Andrew Booth | officer: Chief Financial Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Andrew Lo | director | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
John Hamer | director, 10 percent owner | PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528 |
Ester Falconer | officer: Chief Technology Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Hansen Carl L. G. | director, 10 percent owner, officer: Chief Executive Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Tryn Stimart | officer: Chief Legal Officer | C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1 |
Peter Thiel | director | 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069 |
Dcvc Bio, L.p. | 10 percent owner | 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301 |
Dcvc Bio Gp, Llc | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
Zachary Bogue | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
Matthew Ocko | 10 percent owner | 270 UNIVERSITY AVENUE, PALO ALTO CA 94301 |
From GuruFocus
By GuruFocus Research • 08-08-2024
By GuruFocus News • 11-01-2024
By Business Wire • 01-21-2025
By Business Wire • 07-31-2024
By Business Wire • 08-06-2024
By GuruFocus News • 02-28-2025
By Business Wire • 04-03-2024
By Business Wire • 01-13-2025
By Business Wire • 10-04-2024
By Business Wire • 02-27-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.